prazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 2240 2955-38-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prazepam
  • sedapran
  • trepidan
  • verstran
  • prazene
A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.
  • Molecular weight: 324.81
  • Formula: C19H17ClN2O
  • CLOGP: 3.93
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 32.67
  • ALOGS: -4.91
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.08 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,EIF2AK3,GRK2,MAPK10,MAPK7,PDK1,PDK2,PDK4 8
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.407 Moderate 0.67
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.984 % Moderate 0.67

Approvals:

DateAgencyCompanyOrphan
None FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Poisoning deliberate 504.52 39.58 126 4616 16360 90607345
Coma 467.57 39.58 166 4576 72466 90551239
Somnolence 271.75 39.58 156 4586 208928 90414777
Drug abuse 167.50 39.58 83 4659 82264 90541441
Intentional overdose 162.96 39.58 85 4657 93749 90529956
Altered state of consciousness 154.03 39.58 59 4683 31473 90592232
Suicide attempt 127.13 39.58 67 4675 75332 90548373
Toxicity to various agents 120.74 39.58 108 4634 287738 90335967
Drug use disorder 114.63 39.58 34 4708 8309 90615396
Miosis 110.34 39.58 34 4708 9450 90614255
Drug dependence 105.39 39.58 44 4698 29283 90594422
Electrocardiogram QT prolonged 98.87 39.58 56 4686 72400 90551305
Mydriasis 95.01 39.58 34 4708 14978 90608727
Bezoar 94.04 39.58 23 4719 2711 90620994
Hepatocellular injury 86.09 39.58 38 4704 28920 90594785
Hypotonia 80.38 39.58 28 4714 11398 90612307
Sopor 75.39 39.58 33 4709 24611 90599094
Hypothermia 68.40 39.58 27 4715 15548 90608157
Disturbance in attention 65.82 39.58 37 4705 47072 90576633
Substance use disorder 64.45 39.58 16 4726 2004 90621701
Hypotension 64.38 39.58 82 4660 325315 90298390
Bladder dilatation 64.12 39.58 14 4728 1001 90622704
Prothrombin time ratio decreased 58.83 39.58 13 4729 982 90622723
Prescription form tampering 57.10 39.58 12 4730 715 90622990
Disorientation 51.92 39.58 31 4711 44083 90579622
Respiratory acidosis 49.89 39.58 18 4724 8101 90615604
Bradycardia 42.17 39.58 35 4707 83812 90539893
Overdose 41.44 39.58 46 4696 157663 90466042
Confusional state 41.27 39.58 73 4669 386132 90237573
Hyperlactacidaemia 40.48 39.58 13 4729 4123 90619582
Congestive cardiomyopathy 40.35 39.58 15 4727 7339 90616366
Congestive hepatopathy 40.08 39.58 12 4730 3021 90620684
Bradyphrenia 39.85 39.58 15 4727 7597 90616108

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 308.86 34.70 122 2865 53432 42564916
Drug abuse 146.59 34.70 91 2896 104680 42513668
Miosis 141.98 34.70 48 2939 13398 42604950
Somnolence 121.97 34.70 91 2896 141014 42477334
Poisoning deliberate 106.25 34.70 36 2951 10098 42608250
Drug use disorder 97.78 34.70 34 2953 10299 42608049
Housebound 73.55 34.70 13 2974 226 42618122
Hepatic cytolysis 57.89 34.70 31 2956 26813 42591535
Pneumonia aspiration 53.85 34.70 37 2950 50041 42568307
Substance use disorder 52.13 34.70 18 2969 5327 42613021
Intentional overdose 46.05 34.70 34 2953 51422 42566926
Altered state of consciousness 44.75 34.70 27 2960 29232 42589116
Suicide attempt 44.75 34.70 32 2955 46068 42572280
Bladder dilatation 43.56 34.70 12 2975 1678 42616670
Drug dependence 39.79 34.70 25 2962 29069 42589279
Toxicity to various agents 39.55 34.70 63 2924 229073 42389275
Wrong patient 38.79 34.70 9 2978 630 42617718
Respiratory depression 38.46 34.70 21 2966 18847 42599501

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 744.69 31.72 286 7365 117583 110464065
Poisoning deliberate 559.54 31.72 160 7491 26171 110555477
Somnolence 380.77 31.72 243 7408 297206 110284442
Drug abuse 246.59 31.72 153 7498 177258 110404390
Miosis 242.92 31.72 81 7570 21902 110559746
Drug use disorder 205.27 31.72 68 7583 18006 110563642
Intentional overdose 183.24 31.72 114 7537 132387 110449261
Altered state of consciousness 182.57 31.72 86 7565 57540 110524108
Suicide attempt 166.20 31.72 98 7553 103296 110478352
Toxicity to various agents 143.55 31.72 171 7480 480384 110101264
Mydriasis 118.99 31.72 48 7603 22109 110559539
Substance use disorder 109.75 31.72 34 7617 7256 110574392
Bladder dilatation 105.19 31.72 26 7625 2413 110579235
Drug dependence 95.25 31.72 53 7598 49967 110531681
Hepatocellular injury 94.64 31.72 53 7598 50589 110531059
Electrocardiogram QT prolonged 84.96 31.72 66 7585 108894 110472754
Hypotension 80.75 31.72 136 7515 523713 110057935
Bezoar 78.67 31.72 23 7628 4031 110577617
Pneumonia aspiration 71.70 31.72 53 7598 81180 110500468
Respiratory acidosis 70.95 31.72 29 7622 13797 110567851
Housebound 65.12 31.72 13 7638 450 110581198
Disturbance in attention 62.83 31.72 44 7607 61951 110519697
Hypotonia 60.81 31.72 27 7624 15718 110565930
Intentional product misuse 60.03 31.72 59 7592 132845 110448803
Hypothermia 58.77 31.72 31 7620 26271 110555377
Sopor 56.95 31.72 34 7617 36512 110545136
Overdose 54.92 31.72 74 7577 233720 110347928
Hepatic cytolysis 53.30 31.72 38 7613 55015 110526633
Tachycardia 52.11 31.72 71 7580 226574 110355074
Respiratory depression 50.46 31.72 30 7621 31971 110549677
Prothrombin time ratio decreased 49.14 31.72 13 7638 1579 110580069
Wrong patient received product 48.42 31.72 18 7633 6656 110574992
Mitral valve disease 47.47 31.72 15 7636 3410 110578238
Confusional state 44.22 31.72 99 7552 468581 110113067
Drug ineffective 43.27 31.72 26 7625 1520514 109061134
Speech disorder 43.04 31.72 35 7616 61534 110520114
Cerebral haematoma 42.02 31.72 18 7633 9614 110572034
Bradycardia 40.80 31.72 52 7599 155465 110426183
Disorientation 38.84 31.72 35 7616 70636 110511012
Antipsychotic drug level increased 36.96 31.72 15 7636 7000 110574648
Hyperkalaemia 36.55 31.72 46 7605 135750 110445898
Arthralgia 34.91 31.72 6 7645 779626 109802022
Echolalia 34.81 31.72 8 7643 543 110581105
Chronic actinic dermatitis 34.65 31.72 5 7646 21 110581627
Drug detoxification 34.30 31.72 8 7643 580 110581068
Loss of consciousness 34.22 31.72 54 7597 196252 110385396
Vasoplegia syndrome 33.44 31.72 13 7638 5426 110576222
Retroplacental haematoma 32.54 31.72 6 7645 135 110581513

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05BA11 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
CHEBI has role CHEBI:35474 anxiolytic drug

Related Drugs by ATC class:

N05BA Benzodiazepine derivatives 23 drugs
adinazolamalprazolambentazepambromazepamcamazepamchlordiazepoxideclobazamclorazepateclotiazepamcloxazolamdiazepamethyl loflazepate show all 23 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Disorder of lung contraindication 19829001 DOID:850
Borderline personality disorder contraindication 20010003 DOID:10930
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Decreased respiratory function contraindication 80954004
Kidney disease contraindication 90708001 DOID:557
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Pregnancy, function contraindication 289908002
Coma contraindication 371632003
Porphyria contraindication 418470004
Behavioral Disorders contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.89 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
4018633 VUID
N0000146946 NUI
D00470 KEGG_DRUG
4018633 VANDF
C0032910 UMLSCUI
CHEBI:8362 CHEBI
CHEMBL969 ChEMBL_ID
DB01588 DRUGBANK_ID
D011222 MESH_DESCRIPTOR_UI
4890 PUBCHEM_CID
7275 IUPHAR_LIGAND_ID
1727 INN_ID
Q30VCC064M UNII
8627 RXNORM
001459 NDDF
387417001 SNOMEDCT_US
74065006 SNOMEDCT_US

Pharmaceutical products:

None